About Adagene
Adagene is a company based in Suzhou (China) founded in 2012 by Peter Luo. Adagene has raised $155 million across 5 funding rounds from investors including WuXi AppTec, General Atlantic and Sanofi. The company has 138 employees as of December 31, 2024. Adagene operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Suzhou, China
- Employees 138 as on 31 Dec, 2024
- Founders Peter Luo
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adagene, Inc. Sponsored Adr
-
Annual Revenue
$103.2 K (USD)-99.43as on Dec 31, 2024
-
Net Profit
-$33.42 M (USD)-76.41as on Dec 31, 2024
-
EBITDA
-$35.03 M (USD)-34.69as on Dec 31, 2024
-
Total Equity Funding
$155 M (USD)
in 5 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Jul 01, 2025
-
Investors
WuXi AppTec
& 12 more
-
Employee Count
138
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adagene
Adagene is a publicly listed company on the NASDAQ with ticker symbol ADAG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Adagene
Unlock access to complete
Unlock access to complete
Funding Insights of Adagene
Adagene has successfully raised a total of $155M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adagene
Adagene has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include WuXi AppTec, General Atlantic and Sanofi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on global markets
|
Locked | Locked | Locked | |
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for Adagene
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adagene
Investment portfolio details for Adagene
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adagene
Detailed financials for Adagene
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adagene Comparisons
Peer comparison for Adagene
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adagene
Adagene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Adagene
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adagene
Complete news archive for Adagene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adagene
Adagene was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Adagene is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Peter Luo is the current CEO of Adagene. They have also founded this company.
Adagene is a funded company, having raised a total of $155M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Adagene is 138.
Annual revenue of Adagene is $103.2K as on Dec 31, 2024.
Adagene was founded in 2012 in Suzhou, China, and operates in the biotechnology sector focused on cancer immunotherapy. Antibodies are developed, including ADG106 as an agonist for CD137 in metastatic solid tumors, ADG126 targeting CTLA4 for cancer therapy, and ADG116 targeting a CTLA4 epitope in metastatic solid tumors and relapsedrefractory non-Hodgkins lymphoma. Operations center on advancing these therapies for oncology applications.
Adagene's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Yes, Adagene is publicly traded on NASDAQ under the ticker symbol ADAG.
Adagene has 13 investors. Key investors include WuXi AppTec, General Atlantic, Sanofi, Fidelity International, and Eight Roads Ventures.
The ticker symbol of Adagene is ADAG on NASDAQ.